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Five exposures of baboons to the attenuated schistosome vaccine gave greater protection than three expo-
sures, but this attenuation was not sustained when challenge was delayed. Within the scope of the data
collected, fecal egg counts and circulating antigen levels did not accurately predict the observed worm burdens.
Levels of immunoglobulin G at challenge correlated best with protection, but there was little evidence of a
recall response.
The olive baboon (Papio anubis) provides a robust primate
model for the study of schistosomiasis (7, 10) and has already
been the subject of limited experiments with the radiation-
attenuated (RA) vaccine (2). Given the efficacy of this vaccine
in rodents, it is important to demonstrate that it represents a
realistic paradigm for a human vaccine incorporating defined
antigens. In one study, 50% protection was achieved after
three vaccinations (14), and in another study, 80% protec-
tion was achieved after four vaccinations with a shorter interval
between the last vaccination and challenge (9). However, while
three exposures of vervet monkeys elicited 48% protection,
increasing the number to five exposures resulted in only 39%
protection (15), suggesting that immunoregulatory mecha-
nisms impose a ceiling on protection. In this study, we sought
to determine whether the protective immunity induced in the
baboon by the RA vaccine could be boosted to a high level and
then sustained.
Juvenile olive baboons ranging in weight from 4.6 to 4.9 kg
were used, and on the basis of final weight (9 kg), none
reached sexual maturity before perfusion. They were housed
according to international standards and guidelines for pri-
mates, and all experimental procedures were approved by in-
dependent scientific and ethical committees at the Institute of
Primate Research, Nairobi, Kenya. All exposures to irradiated
and normal cercariae were as described in previous work (14),
using a different skin site on the abdomen, groin, or axilla on
each occasion to avoid interference from any potential local
inflammation. The degree of vaccine-induced protection was
determined by the number of adult worms recovered from
baboons at 6 weeks postchallenge by portal perfusion (11, 14).
As an indirect measure of worm burden, the mean number of
eggs per gram of feces was determined on three 50-mg fresh
fecal samples at weeks 4, 5, and 6 postchallenge by using the
Kato/Katz smear technique (12). Samples of either 5 ml or 20
ml of blood were obtained from test animals, at intervals
throughout the experiments, for serum or recovery of periph-
eral blood mononuclear cells (PBMC), respectively (14); sam-
pling of controls began at the time of challenge. For assays of
antibody and cellular responses, the following parasite antigens
were used: material released during cercarial transformation
into schistosomula from hours 0 to 3 (RAP); soluble proteins
from lung schistosomula (SLAP); and soluble proteins from
eggs (SEA) (1, 6). Concanavalin A (Sigma, Dorset, United
Kingdom) was used in cell assays as a positive control at a
concentration of 10 l/ml. Lymphocyte proliferation was mea-
sured after 72 h (14), and cytokine production was measured
after 96 h of culture. Interleukin-5 (IL-5) and gamma inter-
feron (IFN-) were measured by capture enzyme-linked im-
munosorbent assay (ELISA), using anti-human reagents (5).
Antigen-specific immunoglobulin M (IgM) and IgG antibodies
were measured by ELISA (7, 14). Plates were coated overnight
with RAP (0.25 g/ml for IgM; 1 g/ml for IgG), SLAP (2 g/
ml), or SEA (5 g/ml); after blocking with 3% bovine serum
albumin in phosphate-buffered saline-Tween 20 (0.05%), sera
were diluted to the following concentrations: for RAP, 1/3,200
for IgM and 1/6,400 for IgG; for SLAP, 1/5,000; and for SEA,
1/12,000. The plates were subsequently probed with horserad-
ish peroxidase-labeled rabbit anti-monkey IgM or IgG (Sigma)
at a 1:2,000 dilution, and the reactions were developed with
tetramethylbenzidine substrate (Kirkegaard and Perry Labs,
Gaithersburg, Md.). As a second indirect estimate of worm
burden, schistosome circulating anodic antigen (CAA), which
originates in the gut of blood-feeding stages in the portal
system (4), was measured by antigen capture ELISA using a
pair of specific monoclonal antibodies (3, 8). Data from all
assays were analyzed by a two-tailed Student’s t test; differ-
ences between groups were considered significant at a P value
of 0.05.
We first wished to discover whether increasing the number
of vaccinations would enhance the level of protection. Two
groups of five baboons were vaccinated three or five times
(designated groups 3x and 5x) with 9,000 RA cercariae at
4-week intervals. The experiment was synchronized so that the
first exposure of the 3x group coincided with the third exposure
of the 5x group. Thus, 3 weeks after the last vaccination, both
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test groups together with a group of five control animals were
challenged with 1,000 normal cercariae from the same batch.
The mean worm burden of the challenge control group (Fig.
1a) was much higher than those of the 3x and 5x vaccinated
groups, representing 54 and 86% protection against challenge,
respectively. Comparison of fecal egg counts (Fig. 1b) revealed
a substantially lower output in the 3x and 5x groups compared
to the controls, equating to 89 and 94% protection. Estimation
of CAA in the serum immediately prior to perfusion (Fig. 1c)
also indicated much lower worm burdens in the 3x and 5x
groups than were actually recovered, equating to 84 and 99%
protection.
We then sought to determine whether the high level of
protection would be sustained for a significant period, a crucial
requirement for an effective vaccine. Two groups of five ba-
boons were vaccinated five times at 4-week intervals before
they and their respective controls were challenged with 1,000
normal cercariae at either 3 weeks (VC3) or 12 weeks (VC12)
after the last vaccination. The difference in mean worm bur-
dens between the 3-week challenge controls and the VC3
group at perfusion amounted to 72% protection, while that
between the 12-week challenge controls and the VC12 group
represented only 53% protection (Fig. 1d). In contrast, the
indirect estimates of worm burden suggested that protection
did not wane, with fecal egg counts indicating identical values
in both groups (79%; Fig. 1e), and circulating antigen levels
indicated a higher protection in the VC12 than in the VC3
group (85% versus 74%; Fig. 1f).
Immunological parameters were monitored throughout both
experiments, and as similar profiles were obtained for both
groups vaccinated 5 times and challenged at 3 weeks, only
those from the second experiment are presented. The nonspe-
cific reactivity of PBMC, determined by concanavalin A stim-
ulation, was in the range of 6  104 to 8  104 cpm/well
throughout (data not shown). Furthermore, there was no up-
ward drift in the baseline [3H]thymidine incorporation by un-
stimulated cultures with successive exposures to vaccinating
parasites, indicating an absence of generalized immune system
stimulation. When the proliferation of PBMC in response to
SLAP (Fig. 2a and b) and RAP (data not shown) was moni-
tored, [3H]thymidine incorporation revealed only a small, non-
sustained response in both the VC3 and VC12 groups, sug-
gesting that even irradiated larvae are poorly immunogenic.
Moreover, there was little evidence that normal cercariae pro-
vided a significant boost in responsiveness to antigens after
challenge. (These results argue against the view that trickle
infections of individuals in areas in which the parasite is en-
demic might continually prime the immune response to incom-
ing larvae.) However, there was a dramatic rise in incorpora-
FIG. 1. Protection against challenge estimated by worm burden
(number of worms recovered per animal) (a and d), fecal egg output
(number of eggs per gram of feces) (b and e), and levels of CAA (c and
f) in experiments 1 (a, b, and c) and 2 (d, e, and f). Percentage pro-
tection was calculated using the formula (C V)/C  100, where V is
the worm burden of the vaccinated group and C is the worm burden of
the challenge control group. Significances are given for the absolute
values of each parameter in the vaccinated groups relative to their
respective controls. ***, P  0.001; **, P  0.01; *, P  0.05. Values
depicted are means  standard errors of the mean (SEM) for results
from five animals.
FIG. 2. Cellular responses over the time course of experiment 2.
Incorporation of [3H]thymidine by PBMC after stimulation by SLAP,
with a 3-week interval (a) or a 12-week interval (b) between the last
vaccination and challenge. Closed circles represent values for vacci-
nated groups; open circles represent values for control groups. Arrows
correspond to time of challenge. Values depicted are means  SEM
for results from five animals.
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tion at 6 weeks in the VC3 group and its control, undoubtedly
the result of egg deposition; this was not seen in the VC12
group or its control. The limited peripheral responses after
vaccination were matched by low cytokine production (400
pg of both IFN- and IL-5/ml), making it impossible to delin-
eate distinct Th1 or Th2 patterns (data not shown). The in-
ability to detect a prominent cytokine response was not due to
a failure of the anti-human reagents to capture baboon IFN-
or IL-5, because where egg deposition was evident at 6 weeks
postchallenge, SEA-stimulated cultures contained up to 2,590
pg of IFN-/ml and 837 pg of IL-5/ml.
Antibody responses were a more informative indicator of
immune status. IgM reactive with larval secretions (RAP) rose
rapidly to a peak after two vaccinations before declining in a
sawtooth pattern (Fig. 3a and b), indicating that this isotype is
not crucial for protection. At 6 weeks postchallenge in both
control groups, there was a dramatic rise in IgM responses,
mirrored to a much smaller extent in the vaccinated groups,
coinciding with the onset of egg deposition. IgG levels, in
contrast, rose progressively in a sawtooth fashion with succes-
sive vaccinations in both VC3 and VC12 groups (Fig. 3c and
d); the former group received its challenge virtually at the peak
of the IgG response, whereas levels had declined by two-thirds
when the latter group was challenged. The sawtooth antibody
profile associated with priming, where the boost provided by
vaccination rapidly wanes, is an unusual feature. We can rule
out a contribution from CAA because negligible amounts were
detected prior to the onset of blood feeding after challenge.
The best correlation coefficient (0.43) between antibody re-
sponse and protective immunity was obtained by comparing
IgG levels in response to RAP at challenge with the percentage
protection of individual animals at perfusion, suggesting that
this isotype mediates the effector response. It was noteworthy
that once vaccination ceased, specific IgG levels went into a
rapid decline, with no boost provided by the challenge before
egg deposition began. At the 6-week postchallenge sampling,
the VC12 group and both controls showed a significant rise in
IgG responses to RAP compared to the 4-week values (P 
0.01). Moreover, both IgM and IgG responses to SEA at 6
weeks were virtually superimposable onto those to larval se-
cretions (data not shown); this result is readily explained by the
cross-reactivity of the two antigen preparations.
As the principal purpose of the experiments was to measure
protection, biopsies of skin exposure sites were precluded since
they would remove unknown numbers of parasites. Further-
more, we sought to avoid generating localized dermal re-
sponses by applying cercariae to different sites on each occa-
sion. However, we were able to compare hepatic responses in
all animals at 6 weeks postchallenge. Moderate to severe gran-
ulomatous inflammation was visible in all challenge controls
but was either absent or mild in vaccinated animals. Histology
further revealed that controls formed significantly larger gran-
ulomas than their vaccinated counterparts (data not shown).
Thus, prior exposure to attenuated larvae appears to amelio-
rate the hepatic response to eggs.
The reduction in worm burden in test animals, relative to
controls, is the unequivocal measure of vaccination success. On
this basis we conclude that increasing the number of vaccina-
tions boosts protection in baboons to very high levels. If such
a level could be achieved with a human vaccine, it would have
FIG. 3. Humoral responses over the time course of the duration of the experiment in groups with a 3-week interval (a and c) or a 12-week
interval (b and d) between vaccination and challenge. IgM (a and b) and IgG (c and d) reactivities against RAP are shown. Closed circles represent
values for vaccinated groups; open circles represent values for control groups. Arrows correspond to time of challenge. Values depicted are means
 SEM for results from five animals.
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an impact on both morbidity and transmission. However, in the
absence of restimulation, the high level of protection is not
sustained. Assuming that protection is antibody-mediated, the
reason protection is not sustained is probably the inability to
maintain antibody titer. This result suggests that a recombinant
antigen replacement will require a vaccine formulation that
maintains high antibody titers for an extended period. Such a
strategy may be crucial to vaccination success because parasites
may only be vulnerable to immune attack for a short period
after penetration, leaving insufficient time for a secondary re-
sponse to be mounted before they have become established.
A major problem that will need to be addressed in trials of
human schistosomiasis vaccines is the impossibility of deter-
mining worm burden directly as the measure of protection. We
have, for the first time, evaluated vaccine efficacy in a primate
host by comparing actual worm burdens with the indirect al-
ternatives of number of eggs per gram of feces and CAA levels
in serum. These parameters are routinely used for diagnosis of
schistosome infection in humans (3, 13), but their ability to
predict worm burden cannot be validated. We found that both
provided overestimates of protection, relative to worm burden,
in three out of the four groups. For egg counts, a possible
explanation is that perfusions were performed shortly after the
start of oviposition. Thus, if immune responses delayed para-
site arrival in the portal tract of vaccinated animals, eggs would
appear later in the feces of vaccinated animals than in that of
controls. In future experiments, we will use a later perfusion
time to resolve this issue. The discrepancies between worm
burden and circulating antigen, which originates primarily in
the worm gut (4), are more difficult to reconcile, as blood
feeding commences upon arrival of parasites in the liver some
weeks before perfusion. One potential explanation is that there
are differences in the rates of clearance of circulating antigen
immune complexes in vaccinated groups and control groups. A
second explanation is that female worms in particular may be
rendered less fit by immune pressure; this could be reflected
both in blood feeding or regurgitation of gut contents and in
egg output. Such an antifecundity effect would be a valuable
adjunct to successful vaccination, but a larger data set is
needed before its existence can be confirmed.
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